Skip Ribbon Commands
Skip to main content
A- A A+

Find a Doctor

Dr Daniel Huang

Designations:
  • Consultant, Division of Gastroenterology & Hepatology, Department of Medicine, National University Hospital
  • Consultant, Adult Liver Transplantation Programme, National University Centre for Organ Transplantation, National University Hospital
  • Assistant Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore
Qualifications:
MBBS (S'pore), MMED (Int Med)(S'pore), MRCP (UK)
Specialties:
Medicine, Organ Transplantation
Sub-Specialties:
Adult Liver Transplantation Programme, Gastroenterology & Hepatology
Special Interests:
 ​

Biosketch

Dr. Daniel Q. Huang graduated from the Yong Loo Lin School of Medicine, National University of Singapore. Presently, Dr. Huang is an Assistant Professor at the National University of Singapore and a transplant hepatologist at the National University Hospital. He leads hepatocellular carcinoma research in the Division of Gastroenterology.

Dr. Huang's research interest is in the early detection and prevention of hepatocellular carcinoma in non-alcoholic fatty liver disease and viral hepatitis. Dr. Huang is working on non-invasive strategies to detect and risk stratify chronic liver disease and hepatocellular carcinoma by leveraging advanced imaging-, genomic-, RNA-, meta-analytic-, and microbiome-based approaches. He has published more than 100 peer-reviewed articles, with first or corresponding author publications in journals such as Cell Metabolism, Gastroenterology, Hepatology, Nature Reviews Gastroenterology and Hepatology, the Lancet Gastroenterology and Hepatology, and the Lancet Oncology. He has received awards for his research from the American Association for the Study of Liver Diseases (AASLD), and the European Association for the Study of the Liver (EASL). Dr. Huang has been an invited speaker at the annual scientific meetings of the American Association for the Study of Liver Diseases (AASLD), the American Association for Cancer Research (AACR), and the Asia Pacific Association for the Study of the Liver (APASL). He currently serves on the editorial board of Alimentary Pharmacology and Therapeutics

Area of Interest:

  • Hepatocellular carcinoma
  • Nonalcoholic fatty liver disease
  • Cirrhosis
  • Non-invasive tests for fibrosis and steatosis
  • Chronic hepatitis B

Journals & Publications


  1. Huang, D. Q., Singal, A. G., Kono, Y., et al. (2022). Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metabolism, 34(7), 969-977.e2. doi:10.1016/j.cmet.2022.05.003
  2. Huang, D. Q., Wilson, A.W, Behling, C. et al. Fibrosis Progression Rate in Biopsy-proven Nonalcoholic Fatty Liver Disease among People with Diabetes versus People without Diabetes: A Multicenter Study. Gastroenterology (2023).
  3. Tan, D. J. H., Ng, C. H.,.,. . . and Huang, D. Q. (2022). Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. The Lancet Oncology, 23(4), 521-530. doi:10.1016/S1470-2045(22)00078-X
  4. Huang, D. Q., Fowler, K. J., Liau, J., et al. (2022). Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 55(7), 820-827. doi:10.1111/apt.16844
  5. Huang D.Q., Terrault NA, Tacke F, et al. Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol. 2023 Mar 28:1–11. doi: 10.1038/s41575-023-00759-2.
  6. Huang D.Q., Tran A, Yeh ML, et al. Antiviral therapy substantially reduces hepatocellular carcinoma risk in chronic Hepatitis B patients in the indeterminate phase. Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000459.
  7. Huang D.Q., Nourredin N, Ajmera V, et al. Type 2 Diabetes Mellitus, Hepatic Decompensation and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease: Individual Participant Data Meta-analysis. The Lancet Gastroenterology and Hepatology 2023 (in press).
  8. Huang D.Q., Sharpton SR, Amangurbanova M, et al. Clinical Utility of Combined MRI-PDFF and ALT Response in Predicting Histologic Response in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2022 Sep 6:S1542-3565(22)00832-1. doi: 10.1016/j.cgh.2022.08.036.
  9. Zheng M, Huang D.Q., Konkwo C, et al. Genomic analysis of lean individuals with NAFLD identifies monogenic disorders in a prospective cohort study. JHEP Rep. 2023 Feb 2;5(4):100692.
  10. Huang, D. Q., Muthiah, M. D., Zhou, L et al. (2021). Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy. Cellular and Molecular Gastroenterology and Hepatology, 11(5), 1313-1325. doi:10.1016/j.jcmgh.2020.12.009


Professional Memberships

  • Gastroenterological Society of Singapore (GESS)
  • American Association for the Study of Liver Diseases
  • Fellow of the Royal College of Physicians (UK)


 

Back to Top